• LAST PRICE
    1.1100
  • TODAY'S CHANGE (%)
    Trending Up0.1590 (16.7192%)
  • Bid / Lots
    1.1000/ 37
  • Ask / Lots
    1.1100/ 17
  • Open / Previous Close
    0.9400 / 0.9510
  • Day Range
    Low 0.9299
    High 1.1200
  • 52 Week Range
    Low 0.6900
    High 2.2900
  • Volume
    1,036,109
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 0.951
TimeVolumeKRON
09:32 ET74270.9299
09:36 ET1000.9399
09:38 ET176760.978
09:39 ET100941.03
09:41 ET42441
09:43 ET176901.04
09:45 ET192251.046
09:48 ET197231.05
09:50 ET197821.08
09:52 ET18001.07
09:54 ET235591.062
09:56 ET74321.06
09:57 ET35001.06
09:59 ET132881.07
10:01 ET384611.0792
10:03 ET795521.02
10:06 ET30791.01
10:08 ET2441.0001
10:10 ET132011
10:12 ET1001
10:14 ET88521
10:15 ET48801.04
10:17 ET56191.05
10:19 ET52571.05
10:21 ET59501.06
10:24 ET84121.05
10:26 ET68341.08
10:28 ET113861.06
10:30 ET126001.0601
10:32 ET14591.07
10:33 ET111751.08
10:35 ET74001.08
10:37 ET169651.09
10:39 ET150521.08
10:42 ET310401.08
10:44 ET141721.065
10:46 ET66481.0699
10:48 ET24001.07
10:50 ET3641.06
10:51 ET2001.06
10:53 ET53091.07
10:55 ET60391.07
10:57 ET117981.07
11:00 ET51311.09
11:02 ET59161.1
11:04 ET70241.0817
11:06 ET195581.08
11:08 ET298971.085
11:09 ET68851.0562
11:11 ET4001.05
11:13 ET17001.04
11:15 ET5731.0405
11:18 ET17001.04
11:20 ET18001.07
11:22 ET87571.05
11:24 ET51581.05
11:26 ET16041.06
11:27 ET48121.06
11:29 ET63001.07
11:31 ET121651.07
11:33 ET126701.08
11:36 ET70771.08
11:38 ET45931.08
11:40 ET104421.09
11:42 ET51441.085
11:44 ET51001.09
11:45 ET163651.1
11:47 ET57541.1
11:49 ET14201.1
11:51 ET46401.1
11:54 ET12001.1
11:56 ET3001.105
11:58 ET65371.1
12:00 ET1001.1
12:02 ET97801.1
12:05 ET3001.1
12:09 ET46511.105
12:12 ET13781.1
12:14 ET3001.1
12:16 ET72601.1
12:18 ET59181.1
12:20 ET180051.1
12:21 ET6881.1
12:23 ET80501.1
12:27 ET90501.105
12:30 ET47341.1
12:32 ET34191.1
12:34 ET5001.1
12:36 ET3001.1
12:38 ET30951.1
12:39 ET10991.1
12:41 ET4001.1
12:43 ET86421.105
12:45 ET32001.1
12:48 ET3111.11
12:50 ET43001.1
12:52 ET114801.1
12:54 ET4001.1
12:56 ET28901.1
12:57 ET4001.1
12:59 ET84501.105
01:01 ET13001.1
01:03 ET6001.1
01:06 ET24001.1
01:08 ET7301.1
01:12 ET282421.1
01:14 ET76011.1
01:15 ET2001.1
01:17 ET8441.1
01:19 ET31991.1
01:21 ET73711.1
01:24 ET53001.1
01:26 ET101001.1
01:28 ET257441.085
01:30 ET24361.075
01:32 ET16001.06
01:33 ET45501.06
01:35 ET4001.06
01:37 ET1001.06
01:39 ET90081.095
01:42 ET67001.095
01:44 ET100871.115
01:46 ET12001.11
01:48 ET2001.105
01:50 ET8991.1
01:51 ET157991.1
01:53 ET9001.1
01:55 ET2001.1
01:57 ET13001.1031
02:00 ET19001.1
02:02 ET14201.1
02:04 ET4001.1
02:06 ET3001.1
02:08 ET270721.1
02:09 ET24251.1
02:11 ET9311.1
02:13 ET2001.1
02:15 ET24001.1
02:18 ET47561.1
02:20 ET12001.11
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesKRON
Kronos Bio Inc
44.6M
-0.6x
---
United StatesKZR
Kezar Life Sciences Inc
49.8M
-0.5x
---
United StatesEVGN
Evogene Ltd
35.2M
-1.5x
---
United StatesDRRX
DURECT Corp
47.2M
-1.7x
---
United StatesLVTX
LAVA Therapeutics NV
60.2M
-2.2x
---
United StatesBLRX
BioLine RX Ltd
56.8M
-0.9x
---
As of 2024-06-11

Company Information

Kronos Bio, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics that target the deregulated transcription that causes cancer and other serious diseases. It is developing KB-0742, its internally discovered oral cyclin dependent kinase 9 (CDK9) inhibitor, for the treatment of MYC-amplified and others transcriptionally addicted solid tumors. It has initiated the Phase 2 portion of its Phase 1/2 clinical trial for KB-0742. It is also developing KB-9558, which inhibits the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 TRN. IRF4 is a key transcription factor driver in multiple myeloma and KB-9558 selectively targets its activity. Its scientific focus is on developing medicines that target deregulated transcription, the hallmark of cancer and other serious diseases. Using its Small Molecule Microarray (SMM) platform or other approaches, it can generate and advance small molecule starting points into drug development candidates.

Contact Information

Headquarters
1300 S. El Camino Real, Suite 400SAN MATEO, CA, United States 94402
Phone
650-781-5200
Fax
302-636-5454

Executives

Non-Executive Independent Chairman of the Board
Arie Belldegrun
President, Chief Executive Officer, Director
Norbert Bischofberger
Chief Financial Officer, Chief Operating Officer, Chief Accounting Officer
Deborah Knobelman
Senior Vice President - Corporate Operations and Legal
Allison Frisbee
Senior Vice President - Research and Development
Charles Lin

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$44.6M
Revenue (TTM)
$7.6M
Shares Outstanding
60.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.77
EPS
$-2.00
Book Value
$2.70
P/E Ratio
-0.6x
Price/Sales (TTM)
5.9
Price/Cash Flow (TTM)
---
Operating Margin
-1,651.92%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.